Head to Head Review: CERo Therapeutics (NASDAQ:CERO) & Sandoz Group (OTCMKTS:SDZNY)

Sandoz Group (OTCMKTS:SDZNY) and CERo Therapeutics (NASDAQ:CERO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

Insider & Institutional Ownership

0.1% of Sandoz Group shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Sandoz Group and CERo Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sandoz Group	0	1	0	1	3.00
CERo Therapeutics	1	3	0	0	1.75

CERo Therapeutics has a consensus price target of $45.00, indicating a potential upside of 92,683.51%. Given CERo Therapeutics’ higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Sandoz Group.

Profitability

This table compares Sandoz Group and CERo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sandoz Group	N/A	N/A	N/A
CERo Therapeutics	N/A	N/A	-209.40%

Volatility and Risk

Sandoz Group has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.

Earnings & Valuation

This table compares Sandoz Group and CERo Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sandoz Group	$10.36 billion	3.31	$1.00 million	N/A	N/A
CERo Therapeutics	N/A	N/A	-$8.30 million	($102.61)	0.00

Sandoz Group has higher revenue and earnings than CERo Therapeutics.

Summary

Sandoz Group beats CERo Therapeutics on 6 of the 9 factors compared between the two stocks.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.